| 1.724 0.034 (2.01%) | 09-17 14:19 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.35 | 1-year : | 2.6 |
| Resists | First : | 2.01 | Second : | 2.23 |
| Pivot price | 1.87  |
|||
| Supports | First : | 1.65 | Second : | 1.38 |
| MAs | MA(5) : | 1.73 |
MA(20) : | 1.92 |
| MA(100) : | 2 |
MA(250) : | 1.83  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 7.3 |
D(3) : | 9.6 |
| RSI | RSI(14): 36.4 |
|||
| 52-week | High : | 4.46 | Low : | 1.03 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ALLO ] has closed above bottom band by 20.6%. Bollinger Bands are 14.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.77 - 1.78 | 1.78 - 1.79 |
| Low: | 1.64 - 1.65 | 1.65 - 1.66 |
| Close: | 1.67 - 1.69 | 1.69 - 1.71 |
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.
Tue, 15 Sep 2026
Citizens reiterates Allogene stock rating on CAR T pipeline progress - Investing.com
Fri, 11 Sep 2026
ALLO News | ALLOGENE THERAPEUTICS INC (NASDAQ:ALLO) - ChartMill
Fri, 11 Sep 2026
Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Wed, 02 Sep 2026
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker - Yahoo Finance
Mon, 31 Aug 2026
Allogene Therapeutics Announces Participation in September Investor Conference - GlobeNewswire
Fri, 28 Aug 2026
Allogene Therapeutics: Is The Market Looking At CAR-T Persistence The Wrong Way? (ALLO) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 345 (M) |
| Held by Insiders | 2.6241e+008 (%) |
| Held by Institutions | 11 (%) |
| Shares Short | 59,710 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.6865e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 11.2 % |
| Return on Equity (ttm) | -22.1 % |
| Qtrly Rev. Growth | 4.64e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -88.32 |
| EBITDA (p.s.) | -2.45583e+008 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -102 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.65 |
| Dividend | 0 |
| Forward Dividend | 5.895e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|